Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Coeur Commences Drilling at Silver North's Tim Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mast Therapeutics MSTX

Healthcare Biotechnology
"Mast Therapeutics Inc is a biopharmaceutical company developing clinical-stage therapies for serious or life-threatening diseases with significant unmet needs. Its product candidate, AIR001, a sodium nitrite solution for inhalation via nebulization."

Recent & Breaking News (NYSEAM:MSTX)

Mast Announces Plans For Development Of Vepoloxamer (MST-188) In Heart Failure

PR Newswire December 9, 2014

Mast Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference On December 3rd

PR Newswire November 26, 2014

New Data From Nonclinical Heart Failure Study To Be Presented At American Heart Association Conference

PR Newswire November 19, 2014

Mast Therapeutics To Present MST-188 Data At 2014 American Society Of Hematology Conference

PR Newswire November 17, 2014

Mast Therapeutics Announces Closing Of Underwritten Public Offering

PR Newswire November 13, 2014

Mast Therapeutics Announces Pricing Of Underwritten Public Offering

PR Newswire November 6, 2014

Mast Therapeutics Announces Underwritten Public Offering

PR Newswire November 5, 2014

Mast Therapeutics Reports Third Quarter 2014 Financial Results

PR Newswire October 31, 2014

Mast Therapeutics Announces Appointment Of Chief Medical Officer

PR Newswire October 2, 2014

Mast Therapeutics Announces Positive Top Line Results From Phase 2 Study Of AIR001 For Pulmonary Arterial Hypertension And AIR001 Clinical Development Plan

PR Newswire September 8, 2014

Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th

PR Newswire September 2, 2014

Mast Therapeutics Announces Management Change

PR Newswire August 29, 2014

Mast Therapeutics Provides Corporate Update And Reports Second Quarter 2014 Financial Results

PR Newswire August 11, 2014

Mast Therapeutics To Present At The Canaccord Genuity 34th Annual Growth Conference On August 14th

PR Newswire August 7, 2014

Vista Partners Publishes August 2014 Macroeconomic & Investment Newsletter

Marketwired August 5, 2014

Mast Announces Appointment Of Howard C. Dittrich M.D. To Board of Directors

PR Newswire June 19, 2014

Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial

PR Newswire June 16, 2014

Mast Therapeutics Reports First Quarter 2014 Financial Results

PR Newswire May 5, 2014

Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease

PR Newswire April 14, 2014

Mast Therapeutics (MSTX) Jumps on Positive MST-188 Data

Equities.com April 14, 2014